The White House Peptide Policy: What the Compounding Proposal Actually Says
Bottom line
On October 14, 2026, the FDA and the Department of Health and Human Services submitted an "interim access policy for compounding using certain peptides" to the White House for review. If finalized, it would let licensed compounding pharmacies make and sell certain unapproved peptides — reportedly including BPC-157 — under temporary enforcement discretion. It would not make any peptide FDA-approved, and FDA's own scientists advised against the move at a July meeting, warning the drugs haven't been adequately tested in clinical trials. The policy is still under White House review; no final terms, eligible substances, or timeline have been made public.
What the proposal is
Compounding pharmacies operate under section 503A of the Food, Drug, and Cosmetic Act, which allows them to prepare customized medications for individual patients — generally only from bulk drug substances that appear on FDA's approved lists or meet specific statutory conditions.
The "interim access policy" now sitting with the White House's Office of Management and Budget would create temporary enforcement discretion: the FDA would choose not to take enforcement action against pharmacies compounding certain peptides, under defined conditions, while longer-term rules are developed. Reuters first reported the filing on October 15, citing the OMB docket entry. The filing itself contains no details of the policy — no list of substances, no pharmacy conditions, no timeline.
Which peptides are involved
The proposal follows a July 2026 meeting of the FDA's Pharmacy Compounding Advisory Committee, which reviewed seven peptides for possible addition to the 503A bulk substances list. The panel recommended six: BPC-157, TB-500, KPV, and MOTS-C, followed by Epitalon and Semax. The seventh, emideltide, was voted down 7-6 with one abstention.
Committee votes are recommendations, not decisions — the FDA is not bound by them and would still need to go through formal rulemaking. The White House filing does not say which substances the interim policy would cover, though the Associated Press, citing two people familiar with the matter, reported it would include popular peptides such as BPC-157.
What FDA scientists said — and what the panel did
According to a KFF Health News investigation published October 19, scientists at the FDA advised against loosening restrictions at the July meeting, warning that the peptides hadn't been adequately vetted in clinical trials. The advisory panel disagreed and voted to ease restrictions anyway.
KFF also reported that many of the panel members are new appointees with financial ties to the peptide industry. Two it named: Haleem Mohammed, chief medical officer of Gameday Men's Health — a men's clinic that sells peptides — who said he voted yes "for patient safety, the greater good, and medical freedom"; and Kris Wusterhausen, founder of an anti-aging company that sells BPC-157, who has publicly claimed the peptide treats acid reflux and neurologic disorders, claims not proven in clinical trials. An HHS spokesperson told KFF that every committee member satisfies the FDA's ethics requirements.
Why drugmakers and some researchers oppose it
In a letter to the FDA, the pharmaceutical trade group PhRMA advised against easing restrictions on unapproved peptides, arguing it would "erode incentives for manufacturers to undertake the substantial time and cost required for FDA approval."
Researchers make a related point: if compounding pharmacies can sell these peptides without FDA approval, nobody will fund the clinical trials needed to find out whether they actually work. USC gerontology scientist Pinchas Cohen told KFF that investors already backed out of funding trials on MOTS-c — a peptide he helped discover — because they worried it couldn't compete with GLP-1 drugs.
Supporters, including HHS Secretary Robert F. Kennedy Jr. and MAHA-aligned advocates, frame the issue as medical freedom and patient access, arguing Americans should be able to obtain peptides that pharmaceutical companies have no financial incentive to develop.
What "enforcement discretion" does and doesn't mean
This is the part most coverage glosses over. An enforcement-discretion policy:
Does NOT change the underlying law.
Does NOT establish that any peptide is safe or effective.
Means only that the FDA would choose not to bring enforcement actions against pharmacies meeting the policy's conditions, for a temporary period.
Unapproved peptides sold under such a policy would still be unapproved drugs. And the safety record of the unregulated market is sobering: CNN reported on October 13 that two women were intubated after receiving experimental peptide injections at a Las Vegas anti-aging conference, with Nevada's pharmacy board citing the doctor involved for prescribing without a state license.
In Australia, emergency department presentations linked to unapproved peptide use rose from 5 a month to 217 a month over the past year.
What happens next
The proposal is under White House review. Possible outcomes: the White House clears it (with or without changes), sends it back, or lets it sit. If cleared, the FDA would issue the interim policy with specific conditions and eligible substances — none of which are public yet. Separately, Semafor reported on October 19 that a peptide industry group is scheduled to meet with the White House about the pending plan.
Timelines are unknowable at this stage. And the longer-term question — whether any of these peptides ever go through proper clinical trials — may get harder, not easier, if an interim policy makes trials commercially unnecessary.
Frequently asked questions
Would this policy make BPC-157 legal?
Not exactly. It would mean the FDA temporarily declines to take enforcement action against licensed pharmacies that compound it under the policy's conditions. BPC-157 would remain unapproved — never evaluated by the FDA for safety or effectiveness.
Does the policy mean these peptides are safe?
No. FDA scientists specifically warned the peptides haven't been adequately vetted in clinical trials. The human evidence for BPC-157 consists of a small 2005 inflammatory-bowel-disease trial summary that FDA scientists called "inadequate," a 16-person knee-pain study with no control group, and a 2025 research review that said the peptide should be "approached with caution" for musculoskeletal injuries.
When could this take effect?
Unknown. The policy is under White House review with no public timeline, and the filing contains no details on eligible substances, pharmacy conditions, or duration.
I'm currently using compounded peptides. What should I do?
Talk to a clinician — ideally one without a financial stake in selling you peptides. Unapproved compounded products vary in identity, purity, and dose, and injectable products carry documented risks of contamination and injury.
This article is educational content, not medical advice. The policy described here is a proposal under White House review, not a final rule, and its terms have not been made public. Talk to a qualified clinician about any health decisions. Our editorial standards: https://www.thepeptidesplace.com/editorial-standards
Sources
KFF Health News, Amy Maxmen. "Four Red Flags and One Truth Amid the Peptide Hype." October 19, 2026.
Reuters. "US FDA takes step to change peptide compounding policy." October 15, 2026.
Global Healthcare Magazine. "FDA Peptide Compounding Policy Change Begins Amid Review." October 2026.
Semafor. "Peptide group to meet with White House over pending regulatory plan." October 19, 2026.
CNN. "People say these peptides hurt them. Their stories are muffled in MAHA's push for medical freedom." October 13, 2026.
Comments